For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Krystal Biotech Inc. (KRYS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Krystal Biotech Inc.
KRYS NASDAQKrystal Biotech Inc. is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for severe, life-threatening, and rare diseases with high unmet medical needs. The company specializes in redosable gene therapies built on a proprietary herpes simplex virus type 1 (HSV-1) vector platform, enabling targeted delivery of therapeutic genes to skin and other tissues. Krystal Biotech’s core area of impact is specialty dermatology, where it offers Vyjuvek, a prescription gene therapy for dystrophic epidermolysis bullosa, a rare inherited skin disorder characterized by extreme fragility and chronic wounds. Beyond dermatology, the company is advancing a pipeline that extends its platform into oncology and respiratory indications, aiming to address complex solid tumors and genetic lung diseases through localized gene delivery. Krystal Biotech operates as a fully integrated enterprise, with in-house CGMP manufacturing facilities to support discovery, clinical development, and commercial supply of its therapies. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a distinct role in the biotechnology market as a leader in redosable gene therapy for rare conditions.
Earnings Schedule
Checked daily · calendar updated Aug 14| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Aug 3, 2026 | $1.91 | $1.79 -6.3% | — | — |
| May 4, 2026 | $1.42 | $1.83 +28.9% | — | — |
| Mar 4, 2026 | $0.06 | $0.15 +150.0% | — | — |
| Feb 17, 2026 | $1.61 | $1.70 +5.6% | — | — |
| Jan 7, 2026 | $1.94 | $2.13 +9.8% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 3, 2026 | 8-K | View |
| Aug 3, 2026 | 10-Q | View |
| Jul 21, 2026 | 8-K | View |
| Jun 26, 2026 | 4 | View |
| Jun 25, 2026 | 144 | View |
| Jun 5, 2026 | 4 | View |
| Jun 5, 2026 | 4 | View |
| Jun 4, 2026 | 144 | View |
| Jun 4, 2026 | 144 | View |
| May 27, 2026 | 4 | View |
| May 26, 2026 | 144 | View |
| May 20, 2026 | 8-K | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 14, 2026 8:46am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.84
Total Equity: $1.22B
Shares: 29,951,000
Total Debt: $0.00
Cash: $496.30M
EBITDA: N/A
Total Debt: $0.00
Cash: $496.30M
Revenue: $389.13M
Revenue: $389.13M
Revenue: $389.13M
Total Equity: $1.22B
Tax Rate: -8.1%
Equity: $1.22B
Total Debt: $0.00
Cash: $496.30M
Current Liabilities: $102.94M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $1.22B
Shares: 29,951,000
Shares: 29,951,000
CapEx: -$11.95M
Shares: 29,951,000
Stock Price: $328.34
Net Income: $204.83M
Income Statement (Annual)
Last updated: Aug 14, 2026 8:46am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $50.7M | $290.5M | $389.1M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $68.3M | $145.2M | $160.4M | $224.8M | $227.8M |
| Operating Income | -$68.3M | -$145.2M | -$109.7M | $65.7M | $161.3M |
| Net Income | -$69.6M | -$140.0M | $10.9M | $89.2M | $204.8M |
| EBITDA | -$65.5M | -$141.1M | — | — | — |
| EPS | $-3.13 | $-5.49 | $0.40 | $3.12 | $7.08 |
| EPS (Diluted) | $-3.13 | $-5.49 | $0.39 | $3.00 | $6.84 |
Balance Sheet (Annual)
Last updated: Aug 14, 2026 8:46am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $341.2M | $161.9M | $358.3M | $344.9M | $496.3M |
| Total Current Assets | $442.3M | $383.8M | $587.9M | $742.0M | $1.0B |
| Total Assets | $626.3M | $558.5M | $818.4M | $1.1B | $1.3B |
| Current Liabilities | $25.7M | $28.8M | $33.1M | $102.0M | $102.9M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $32.7M | $36.2M | $39.7M | $109.5M | $114.2M |
| Total Equity | $593.6M | $522.2M | $778.6M | $946.4M | $1.2B |
| Retained Earnings | -$140.8M | -$280.8M | -$269.8M | -$180.7M | $24.2M |
Cash Flow (Annual)
Last updated: Aug 14, 2026 8:46am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$47.9M | -$100.6M | -$88.8M | $123.4M | $200.9M |
| Capital Expenditure | -$68.3M | -$53.0M | -$11.8M | -$4.2M | -$12.0M |
| Free Cash Flow | -$116.3M | -$153.5M | -$100.6M | $119.2M | $188.9M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $73.0M | -$179.3M | $196.4M | -$13.5M | $151.4M |
Growth Trends (YoY %)
Last updated: Aug 14, 2026 8:46am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | +473.0% | +33.9% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -112.7% | +24.4% | +159.9% | +145.5% |
| Net Income Growth | -101.2% | +107.8% | +715.6% | +129.7% |
| EBITDA Growth | -115.5% | — | — | — |
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Narrative Economics
market-narrative step).
Claude Reading
ai-findings step) when a report is run on this ticker.
GPT Reading
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.